Lu Chen
YOU?
Author Swipe
View article: Cochlear immunology and its therapeutic revolution
Cochlear immunology and its therapeutic revolution Open
Over the past five years, cochlear immunology has experienced a paradigm shift, challenging the long-held perception of the inner ear as an “immune-privileged” site. Our review consolidates recent advancements that elucidate the cochlea’s …
View article: A new horned toad of Boulenophrys (Anura, Megophryidae) was discovered in Hubei Province, China
A new horned toad of Boulenophrys (Anura, Megophryidae) was discovered in Hubei Province, China Open
The diversity of the genus Boulenophrys , with around 72 species identified so far, is still thought to be highly underestimated, as it contains a large number of undescribed cryptic species. The favorable ecological environment of the Dal…
View article: Machine learning unveils hypoxia-immune gene hub for clinical stratification of thyroid-associated ophthalmopathy
Machine learning unveils hypoxia-immune gene hub for clinical stratification of thyroid-associated ophthalmopathy Open
Thyroid-associated ophthalmopathy (TAO) is an autoimmune disorder affecting the orbit, potentially resulting in blindness. This study focused on the role of hypoxia in its pathogenesis through integrative bioinformatics and experimental va…
View article: Figure S2 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Figure S2 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
Schematic of HCC mouse models and serum analysis
View article: Figure S6 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Figure S6 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
CRTC2 condensates promote HCC cell migration and invasion
View article: Figure S4 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Figure S4 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
CRTC2 knockout inhibits HCC cell migration and invasion
View article: Figure S11 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Figure S11 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
CRTC2 facilitates c-Jun targets expression.
View article: Figure S10 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Figure S10 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
Identification of CRTC2–YTHDF2 co-condensate m6A-RNAs.
View article: Figure S13 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Figure S13 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
CRTC2 promotes Lenvatinib resistance in HCC.
View article: Figure S1 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Figure S1 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
Correlation analysis of CRTC2 expression with CNA
View article: Figure S9 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Figure S9 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
CRTC2 promotes HCC progression dependent on YTHDF2.
View article: Figure S8 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Figure S8 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
CRTC2 serves as a scaffold protein to recruit YTHDF2 into condensates.
View article: Figure S3 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Figure S3 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
Knockout of CRTC2 impairs proliferation of HCC cells.
View article: Figure S14 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Figure S14 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
Schematic of AAV8.sgCRTC2 gene therapy in HCC mouse model.
View article: Data from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Data from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
As the third most common cause of cancer-related mortality, hepatocellular carcinoma (HCC) is a global health concern. Despite its prevalence, treatment options are limited, underscoring the need to identify potential therapeutic targets a…
View article: Table S1 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Table S1 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
Relationship between baseline and clinical characteristics of the patient and CRTC2 expression
View article: Figure S5 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Figure S5 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
CRTC2 condensates promote HCC initiation and progression in vivo and in vitro.
View article: Figure S12 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Figure S12 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
Schematic of AAV8.sgCRTC2 gene therapy in DEN/CCl4-HCC model.
View article: Figure S7 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Figure S7 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m<sup>6</sup>A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance Open
The location and function of TurboID-tagged CRTC2 are similar to wild-type CRTC2.
View article: Construction of a C-reactive protein-albumin-lymphocyte index-based prediction model for all-cause mortality in patients on maintenance hemodialysis
Construction of a C-reactive protein-albumin-lymphocyte index-based prediction model for all-cause mortality in patients on maintenance hemodialysis Open
The CALLY index is closely related to the mortality of MHD patients. A nomogram constructed based on CALLY index can effectively evaluate the mortality risk of MHD patients.
View article: Benefit of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score-Matched Study
Benefit of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score-Matched Study Open
For patients with unresectable hepatocellular carcinoma, conversion therapy offers a significantly better prognosis than direct surgery for uHCC patients.
View article: Supplementary Fig. S1 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers
Supplementary Fig. S1 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers Open
Supplementary Fig. S1
View article: Supplementary Fig. S6 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers
Supplementary Fig. S6 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers Open
Supplementary Fig. S6
View article: Supplementary Fig. S13 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers
Supplementary Fig. S13 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers Open
Supplementary Fig. S13
View article: Supplementary Fig. S2 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers
Supplementary Fig. S2 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers Open
Supplementary Fig. S2
View article: Supplementary Fig. S1 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers
Supplementary Fig. S1 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers Open
Supplementary Fig. S1
View article: Supplementary Fig. S8 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers
Supplementary Fig. S8 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers Open
Supplementary Fig. S8
View article: Supplementary Fig. S18 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers
Supplementary Fig. S18 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers Open
Supplementary Fig. S18
View article: Supplementary Fig. S5 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers
Supplementary Fig. S5 from Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers Open
Supplementary Fig. S5